RTN4R and neoplasm: To assess the imaging properties of this nanosphere-peptide conjugate ([177Lu]Lu-DOTA-CNS-cNGR), its organ distribution pattern and tumour affinity were compared with those of the radiolabelled NGR peptide without the nanosphere ([177Lu]Lu-DOTA-cNGR) as well as the peptide-free [177Lu]Lu-labelled CNS ([177Lu]Lu-DOTA-CNS) using B16F10 melanoma tumour-bearing C57BL6 mice.